Cited by 884Cancer-related Molecular PathwaysCancer Genomics and DiagnosticsGenetic factors in colorectal cancer

The DOI matches its Crossref record; 117 of the 117 references it cites were found in a registry or an index.

TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes

Petitjean, A, Achatz, M I W, Borresen-Dale, A L, Hainaut, P, Olivier, M·2007·Oncogene

Open this paper in CoChat — free account

Abstract

A large amount of data is available on the functional impact of missense mutations in TP53 and on mutation patterns in many different cancers. New data on mutant p53 protein function, cancer phenotype and prognosis have recently been integrated in the International Agency for Research on Cancer TP53 database (http://www-p53.iarc.fr/). Based on these data, we summarize here current knowledge on the respective roles of mutagenesis and biological selection of mutations with specific functional characteristic in shaping the patterns and phenotypes of mutations observed in human cancers. The main conclusion is that intrinsic mutagenicity rates, loss of transactivation activities, and to a lesser extent, dominant-negative activities are the main driving forces that determine TP53 mutation patterns and influence tumor phenotype. In contrast, current experimental data on the acquisition of oncogenic activities (gain of function) by p53 mutants are too scarce and heterogenous to assess whether this property has an impact on tumor development and outcome. In the case of inherited TP53 mutations causing Li-Fraumeni and related syndromes, the age at onset of some tumor types is in direct relation with the degree of loss of transactivation capacity of missense mutations. Finally, studies on large case series demonstrate that TP53 mutations are independent markers of bad prognosis in breast and several other cancers, and that the exact type and position of the mutation influences disease outcome. Further studies are needed to determine how TP53 haplotypes or loss of alleles interact with mutations to modulate their impact on cancer development and prognosis.

Integrity signals

Registry

Crossref · 10.1038/sj.onc.1210302

Cites

117 of 117 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
Sørlie, T., Perou, C. M., Tibshirani, R. J., Aas, T., Geisler, S. B., Johnsen, H., Hastie, T. J., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191367098 · Cited by 11,506
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018
p53, the cellular gatekeeper for growth and division
Levine, A. J. (1997) · Cell · doi:10.1016/s0092-8674(00)81871-1 · Cited by 7,693
Surfing the p53 network
Vogelstein, B., Lane, D., & Levine, A. J. (2000) · Nature · doi:10.1038/35042675 · Cited by 6,607 · cited 2×
“191117) encodes a transcription factor which is activated in response to several forms of cellular stress and exerts multiple, antiproliferative functions (Vogelstein et al., 2000).”
Background
Instability and decay of the primary structure of DNA
Lindahl, T. (1993) · Nature · doi:10.1038/362709a0 · Cited by 5,679
Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses
Jones, S., Zhang, X., Parsons, D. W., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Kamiyama, H., Jimeno, A., et al. (2008) · Science · doi:10.1126/science.1164368 · Cited by 3,969
Germ Line p53 Mutations in a Familial Syndrome of Breast Cancer, Sarcomas, and Other Neoplasms
Malkin, D., Li, F. P., Strong, L. C., Fraumeni, J. F., Nelson, C. E., Kim, D. H., Kassel, J., Gryka, M. A., Bischoff, F. Z., Tainsky, M. A., et al. (1990) · Science · doi:10.1126/science.1978757 · Cited by 3,765
Patterns of somatic mutation in human cancer genomes
Greenman, C. D., Stephens, P., Smith, R., Dalgliesh, G. L., Hunter, C., Bignell, G. R., Davies, H. R., Teague, J. W., Butler, A. P., Stevens, C., et al. (2007) · Nature · doi:10.1038/nature05610 · Cited by 3,143
Somatic mutations affect key pathways in lung adenocarcinoma
Ding, L., Getz, G., Wheeler, D. A., Mardis, E. R., McLellan, M. D., Cibulskis, K., Sougnez, C., Greulich, H., Muzny, D. M., Morgan, M. B., et al. (2008) · Nature · doi:10.1038/nature07423 · Cited by 2,681
Crystal Structure of a p53 Tumor Suppressor-DNA Complex: Understanding Tumorigenic Mutations
Cho, Y., Gorina, S., Jeffrey, P. D., & Pavletich, N. P. (1994) · Science · doi:10.1126/science.8023157 · Cited by 2,559
Crypt stem cells as the cells-of-origin of intestinal cancer
Barker, N., Ridgway, R. A., van Es, J. H., van de Wetering, M., Begthel, H., van den Born, M., Danenberg, E., Clarke, A. R., Sansom, O. J., & Clevers, H. C. (2008) · Nature · doi:10.1038/nature07602 · Cited by 2,232
Definition of a consensus binding site for p53
El-Deiry, W. S., Kern, S. E., Pietenpol, J. A., Kinzler, K. W., & Vogelstein, B. (1992) · Nature Genetics · doi:10.1038/ng0492-45 · Cited by 1,985
Transcriptional control of human p53-regulated genes
Riley, T., Sontag, E., Chen, P., & Levine, A. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2395 · Cited by 1,921
Preferential Formation of Benzo[ a ]pyrene Adducts at Lung Cancer Mutational Hotspots in P53
Denissenko, M. F., Pao, A., Tang, M.-S., & Pfeifer, G. P. (1996) · Science · doi:10.1126/science.274.5286.430 · Cited by 1,650
Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database
Petitjean, A., Mathe, E., Kato, S., Ishioka, C., Tavtigian, S. V., Hainaut, P., & Olivier, M. (2007) · Human Mutation · doi:10.1002/humu.20495 · Cited by 1,598
Self-citation
Mutational hot spot in the p53 gene in human hepatocellular carcinomas
Hsu, I., Metcalf, R. A., Sun, T., Welsh, J. A., Wang, N. J., & Harris, C. C. (1991) · Nature · doi:10.1038/350427a0 · Cited by 1,533
Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa
Paillerets, B. B., Kew, M. C., Wands, J. R., & Öztürk, M. (1991) · Nature · doi:10.1038/350429a0 · Cited by 1,452
Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome
Olive, K. P., Tuveson, D. A., Ruhe, Z. C., Yin, B., Willis, N. A., Bronson, R. T., Crowley, D., & Jacks, T. (2004) · Cell · doi:10.1016/j.cell.2004.11.004 · Cited by 1,308
A cancer family syndrome in twenty-four kindreds.
Li, F. P., Fraumeni, J. F., Mulvihill, J. J., Blattner, W. A., Dreyfus, M., Tucker, M., & Miller, R. (1988) · PubMed · Cited by 1,293
The codon 72 polymorphic variants of p53 have markedly different apoptotic potential
Dumont, P., Leu, J. I.-J., Pietra, A. D., George, D. L., & Murphy, M. E. (2003) · Nature Genetics · doi:10.1038/ng1093 · Cited by 1,269
A Single Nucleotide Polymorphism in the MDM2 Promoter Attenuates the p53 Tumor Suppressor Pathway and Accelerates Tumor Formation in Humans
Bond, G. L., Hu, W., Bond, E. E., Robins, H., Lutzker, S. G., Arva, N. C., Bargonetti, J., Bartel, F., Taubert, H., Wuerl, P., et al. (2004) · Cell · doi:10.1016/j.cell.2004.11.022 · Cited by 1,265
An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival
Miller, L. D., Smeds, J., George, J., Vega, V. B., Vergara, L. A., Ploner, A., Yudi Pawitan, Y., Hall, P. N., Klaar, S., Liu, E. T., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506230102 · Cited by 1,256
The IARC TP53 database: new online mutation analysis and recommendations to users
Olivier, M., Eeles, R., Hollstein, M., Khan, M. A., Harris, C. C., & Hainaut, P. (2002) · Human Mutation · doi:10.1002/humu.10081 · Cited by 1,248
Self-citation
p53AIP1, a Potential Mediator of p53-Dependent Apoptosis, and Its Regulation by Ser-46-Phosphorylated p53
Oda, K., Arakawa, H., Tanaka, T., Matsuda, K., Tanikawa, C., Mori, T., Nishimori, H., Tamai, K., Tokino, T., Nakamura, Y., et al. (2000) · Cell · doi:10.1016/s0092-8674(00)00073-8 · Cited by 1,162
Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers
Pfeifer, G. P., Denissenko, M. F., Olivier, M., Tretyakova, N. Y., Hecht, S. S., & Hainaut, P. L. (2002) · Oncogene · doi:10.1038/sj.onc.1205803 · Cited by 1,107
Self-citation
Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome
Lang, G. A., Iwakuma, T., Suh, Y.-A., Liu, G., Rao, V. A., Parant, J. M., Valentin-Vega, Y. A., Terzian, T., Caldwell, L. C., Strong, L. C., et al. (2004) · Cell · doi:10.1016/j.cell.2004.11.006 · Cited by 1,069
p53 and Human Cancer: The First Ten Thousand Mutations
Hainaut, P. L., & Hollstein, M. C. (1999) · Advances in cancer research · doi:10.1016/s0065-230x(08)60785-x · Cited by 999
Self-citation
Role of a p53 polymorphism in the development of human papilloma-virus-associated cancer
Storey, A., Thomas, M., Kalita, A., Harwood, C. A., Gardiol, D., Mantovani, F., Breuer, J., Leigh, I. M., Matlashewski, G., & Banks, L. (1998) · Nature · doi:10.1038/30400 · Cited by 971
Understanding the function–structure and function–mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis
Kato, S., Han, S., Liu, W., Otsuka, K., Shibata, H., Kanamaru, R., & Ishioka, C. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1431692100 · Cited by 895
Small molecule RITA binds to p53, blocks p53–HDM-2 interaction and activates p53 function in tumors
Issaeva, N., Bozko, P. M., Enge, M., Protopopova, M., Verhoef, L. G. G. C., Masucci, M. G., Pramanik, A., & Selivanova, G. (2004) · Nature Medicine · doi:10.1038/nm1146 · Cited by 760
Two Polymorphic Variants of Wild-Type p53 Differ Biochemically and Biologically
Thomas, M., Kalita, A., Labrecque, S., Pim, D., Banks, L., & Matlashewski, G. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.2.1092 · Cited by 698
TP53 mutations and hepatocellular carcinoma: insights into the etiology and pathogenesis of liver cancer
Hussain, S. P., Schwank, J., Staib, F., Wang, X. W., & Harris, C. C. (2007) · Oncogene · doi:10.1038/sj.onc.1210279 · Cited by 643
Beyond Li Fraumeni Syndrome: Clinical Characteristics of Families With p53 Germline Mutations
Hagman, K. D. F., Noltner, K., Buzin, C. H., Gu, D., Wen, C. Y., Nguyen, V. Q., Han, J., Lowstuter, K. J., Longmate, J., Sommer, S. S., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.6959 · Cited by 607
Aristolochic acid and the etiology of endemic (Balkan) nephropathy
Grollman, A. P., Shibutani, S., Moriya, M., Miller, F. W., Wu, L., Moll, U. M., Suzuki, N., Fernandes, A., Rosenquist, T. A., Medverec, Z., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0701248104 · Cited by 603
The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer.
Olivier, M., Langer√∏d, A., Carrieri, P., Bergh, J. C. S., Klaar, S., Eyfjord, J. E., Theillet, C. G., Rodríguez, C., Lidereau, R., Bièche, I., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1029 · Cited by 590
Self-citation
An inherited p53 mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinoma
Ribeiro, R. C., Sandrini, F., Figueiredo, B., Zambetti, G. P., Michalkiewicz, E., Lafferty, A. R., DeLacerda, L., Rabin, M., Cadwell, C., Sampaio, G., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.161479898 · Cited by 541
A common polymorphism acts as an intragenic modifier of mutant p53 behaviour
Marín, M. C., Jost, C. A., Brooks, L. A., Irwin, M. S., O’Nions, J., TIDY, J. A., James, N. D., McGregor, J., Harwood, C. A., Yuluğ, I. G., et al. (2000) · Nature Genetics · doi:10.1038/75586 · Cited by 511
Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype.
Olivier, M., Goldgar, D. E., Sodha, N., Ohgaki, H., Kleihues, P., Hainaut, P. L., & Eeles, R. A. (2003) · PubMed · Cited by 480
Self-citation
Relative frequency and morphology of cancers in carriers of germline TP53 mutations
Birch, J. M., Alston, R. D., McNally, R. J., Evans, D. G. R., Kelsey, A. M., Harris, M., Eden, O. B., & Varley, J. M. (2001) · Oncogene · doi:10.1038/sj.onc.1204621 · Cited by 467
p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM
Song, H., Hollstein, M., & Xu, Y. (2007) · Nature Cell Biology · doi:10.1038/ncb1571 · Cited by 456
Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy
Bergh, J. C. S., Norberg, T., Sjögren, S., Lindgren, A., & Holmberg, L. (1995) · Nature Medicine · doi:10.1038/nm1095-1029 · Cited by 456
p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis
Bergamaschi, D., Gasco, M., Hiller, L., Sullivan, A., Syed, N., Trigiante, G., Yuluğ, I. G., Merlano, M. C., Numico, G., Comino, A., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00079-5 · Cited by 445
Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy
Bullock, A. N., Henckel, J., & Fersht, A. R. (2000) · Oncogene · doi:10.1038/sj.onc.1203434 · Cited by 440
p53 polymorphic variants at codon 72 exert different effects on cell cycle progression
Pim, D., & Banks, L. (2003) · International Journal of Cancer · doi:10.1002/ijc.11548 · Cited by 411
Mutant p53 DNA clones from human colon carcinomas cooperate with ras in transforming primary rat cells: a comparison of the "hot spot" mutant phenotypes.
Hinds, P. W., Finlay, C. A., Quartin, R. S., Baker, S. J., Fearon, E. R., Vogelstein, B., & Levine, A. J. (1990) · PubMed · Cited by 408
Targeted rescue of a destabilized mutant of p53 by an in silico screened drug
Boeckler, F. M., Joerger, A. C., Jaggi, G., Rutherford, T. J., Veprintsev, D. B., & Fersht, A. R. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805326105 · Cited by 398
Structural basis for understanding oncogenic p53 mutations and designing rescue drugs
Joerger, A. C., Ang, H. C., & Fersht, A. R. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0607286103 · Cited by 368
Is p53 Polymorphism Maintained by Natural Selection?
Beckman, G., Birgander, R., lander, A. S. A., Saha, N., Holmberg, P., Kivelä, A., & Beckman, L. E. (1994) · Human Heredity · doi:10.1159/000154228 · Cited by 362
A screen of the complete protein kinase gene family identifies diverse patterns of somatic mutations in human breast cancer
Stephens, P., Edkins, S., Davies, H. R., Greenman, C., Cox, C., Hunter, C., Bignell, G. R., Teague, J. W., Smith, R., Stevens, C., et al. (2005) · Nature Genetics · doi:10.1038/ng1571 · Cited by 333
TP53 mutations in human skin cancers
Giglia‐Mari, G., & Sarasin, A. R. (2003) · Human Mutation · doi:10.1002/humu.10179 · Cited by 298
TP53mutation status and gene expression profiles are powerful prognostic markers of breast cancer
Langerød, A., Zhao, H., Borgan, Ø., Nesland, J. M., Bukholm, I. R., Ikdahl, T., Kåresen, R., Børresen‐Dale, A., & Jeffrey, S. S. (2007) · Breast Cancer Research · doi:10.1186/bcr1675 · Cited by 295
A novel mechanism of tumorigenesis involving pH-dependent destabilization of a mutant p53 tetramer
DiGiammarino, E. L., Lee, A. S., Cadwell, C., Zhang, W., Bothner, B. B., Ribeiro, R. C., Zambetti, G. P., & Kriwacki, R. W. (2001) · Nature Structural Biology · doi:10.1038/nsb730 · Cited by 293
MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner
Bond, G. L., Hirshfield, K. M., Kirchhoff, T., Alexe, G., Bond, E. E., Robins, H., Bartel, F., Taubert, H., Wuerl, P., Hait, W., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0180 · Cited by 287
Polymorphism in wild-type p53 modulates response to chemotherapy in vitro and in vivo
Sullivan, A., Syed, N., Gasco, M., Bergamaschi, D., Trigiante, G., Attard, M., Hiller, L., Farrell, P. J., Smith, P., Lü, X., et al. (2004) · Oncogene · doi:10.1038/sj.onc.1207428 · Cited by 249
p53 Genotypes and Haplotypes Associated With Lung Cancer Susceptibility and Ethnicity
Wu, X. (2002) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/94.9.681 · Cited by 249
Reactivation of Mutant p53 and Induction of Apoptosis in Human Tumor Cells by Maleimide Analogs
Bykov, V. J. N., Issaeva, N., Zache, N., Shilov, A., Hultcrantz, M., Bergman, J., Selivanova, G., & Wiman, K. G. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m501664200 · Cited by 247
TP53 mutation spectra and load: a tool for generating hypotheses on the etiology of cancer.
Olivier, M., Hussain, S. P., de Fromentel, C. C., Hainaut, P. L., & Harris, C. C. (2004) · PubMed · Cited by 243
Self-citation
Screening patients for heterozygous p53 mutations using a functional assay in yeast
Ishioka, C., Frébourg, T., Yan, Y.-X., Vidal, M., Friend, S. H., Schmidt, S., & Iggo, R. D. (1993) · Nature Genetics · doi:10.1038/ng1093-124 · Cited by 243
Analysis of the most representative tumour‐derived p53 mutants reveals that changes in protein conformation are not correlated with loss of transactivation or inhibition of cell proliferation.
Ory, K., Legros, Y., Auguin, C., & Soussi, T. (1994) · The EMBO Journal · doi:10.1002/j.1460-2075.1994.tb06656.x · Cited by 230
The TP53 mutation, R337H, is associated with Li-Fraumeni and Li-Fraumeni-like syndromes in Brazilian families
Achatz, M. I., Olivier, M., Calvez‐Kelm, F. L., Martel‐Planche, G., Lopes, A., Rossi, B. M., Ashton‐Prolla, P., Giugliani, R., Palmero, E. I., Vargas, F. R., et al. (2006) · Cancer Letters · doi:10.1016/j.canlet.2005.12.039 · Cited by 218
Self-citation
A TP53 polymorphism is associated with increased risk of colorectal cancer and with reduced levels of TP53 mRNA
Gemignani, F., Moreno, V. R., Landi, S., Moullan, N., Chabrier, A., Gutiérrez‐Enríquez, S., Hall, J. A., Guinó, E., Peinado, M. A., Capellá, G., et al. (2003) · Oncogene · doi:10.1038/sj.onc.1207305 · Cited by 217
Impact of the MDM2 SNP309 and p53 Arg72Pro polymorphism on age of tumour onset in Li-Fraumeni syndrome
Bougeard, G., Baert-Desurmont, S., Tournier, I., Vasseur, S., Martin, C., Brugières, L., Chompret, A., Paillerets, B. B., Stoppa‐Lyonnet, D., Bonaïti‐Pellié, C., et al. (2005) · Journal of Medical Genetics · doi:10.1136/jmg.2005.037952 · Cited by 216
Germline mutations in the TP53 gene.
Eeles, R. A. (1995) · PubMed · Cited by 213
Characterization of genome-wide p53-binding sites upon stress response
Smeenk, L., van Heeringen, S. J., Koeppel, M., van Driel, M. A., Bartels, S. J. J., Akkers, R. C., Denissov, S., Stunnenberg, H. G., & Lohrum, M. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkn232 · Cited by 211
Methylation, mutation and cancer
Jones, P. A., Rideout, W. M., Shen, J., Spruck, C., & Tsai, Y. (1992) · BioEssays · doi:10.1002/bies.950140107 · Cited by 205
The TP53 codon 72 polymorphism may affect the function of TP53 mutations in breast carcinomas but not in colorectal carcinomas.
Langerød, A., Bukholm, I., Bregård, A., Lønning, P. E., Andersen, T. I., Rognum, T. O., Meling, G. I., Lothe, R. A., & Børresen‐Dale, A. (2002) · PubMed · Cited by 204
Cancer phenotype correlates with constitutional TP53 genotype in families with the Li-Fraumeni syndrome
Birch, J. M., Blair, V., Kelsey, A. M., Evans, D. G., Harris, M., Tricker, K. J., & Varley, J. M. (1998) · Oncogene · doi:10.1038/sj.onc.1202033 · Cited by 200
Differential Transactivation by the p53 Transcription Factor Is Highly Dependent on p53 Level and Promoter Target Sequence
Inga, A., Storici, F., Darden, T. A., & Resnick, M. A. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.24.8612-8625.2002 · Cited by 195
Structures of p53 Cancer Mutants and Mechanism of Rescue by Second-site Suppressor Mutations
Joerger, A. C., Ang, H. C., Veprintsev, D. B., Blair, C. M., & Fersht, A. R. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m500179200 · Cited by 181
BRCA1, BRCA2 and TP53 mutations in very early-onset breast cancer with associated risks to relatives
Lalloo, F. I., Varley, J. M., Moran, A., Ellis, D., O’Dair, L., Pharoah, P. D. P., Antoniou, A. C., Hartley, R., Shenton, A., Seal, S., et al. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2005.11.032 · Cited by 175
Aristolochic acid mutagenesis: molecular clues to the aetiology of Balkan endemic nephropathy-associated urothelial cancer
Arlt, V. M., Stiborová, M., Brocke, J. V., Simões, M. L., Lord, G. M., Nortier, J., Hollstein, M., Phillips, D. H., & Schmeiser, H. H. (2007) · Carcinogenesis · doi:10.1093/carcin/bgm082 · Cited by 173
Retention of the p53 codon 72 arginine allele is associated with a reduction of disease-free and overall survival in arginine/proline heterozygous breast cancer patients.
Bonafè, M., Ceccarelli, C., Farabegoli, F., Santini, D., Taffurelli, M., Barbi, C., Marzi, E., Trapassi, C., Storci, G., Olivieri, F., et al. (2003) · PubMed · Cited by 171
Dominant-negative p53 mutations selected in yeast hit cancer hot spots.
Brachmann, R. K., Vidal, M., & Boeke, J. D. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.9.4091 · Cited by 162
TP53 polymorphisms and lung cancer risk: a systematic review and meta-analysis
Matakidou, A. (2003) · Mutagenesis · doi:10.1093/mutage/geg008 · Cited by 150
p53 Codon 72 Polymorphism and Cervical Neoplasia
Koushik, A., Platt, R. W., & Franco, E. L. (2004) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-083-3 · Cited by 146
Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss of heterozygosity as an important aspect of p53 status in human cancers
Dearth, L. R., Hua, Q., Wang, T., Baroni, T. E., Zeng, J., Chen, S. W., Yi, S. Y., & Brachmann, R. K. (2006) · Carcinogenesis · doi:10.1093/carcin/bgl132 · Cited by 139
Knock-in mice with a chimeric human/murine p53 gene develop normally and show wild-type p53 responses to DNA damaging agents: a new biomedical research tool
Luo, J., Yang, Q., Tong, W., Hergenhahn, M., Wang, Z., & Hollstein, M. C. (2001) · Oncogene · doi:10.1038/sj.onc.1204080 · Cited by 135
p53 polymorphism and risk of cervical cancer
Helland, Å., Langerød, A., Johnsen, H., Olsen, A. O., Skovlund, E., & Børresen‐Dale, A. (1998) · Nature · doi:10.1038/25034 · Cited by 134
Trp53-dependent DNA-repair is affected by the codon 72 polymorphism
Siddique, M. M., & Sabapathy, K. (2006) · Oncogene · doi:10.1038/sj.onc.1209405 · Cited by 128
Ser46 Phosphorylation Regulates p53-Dependent Apoptosis and Replicative Senescence
Feng, L., Hollstein, M., & Xu, Y. (2006) · Cell Cycle · doi:10.4161/cc.5.23.3526 · Cited by 119
TP53 Status and Response to Chemotherapy in Breast Cancer
Bertheau, P., Espié, M., Turpin, E., Lehmann‐Che, J., Plassa, L., Varna, M., Janin, A., & de Thé, H. (2008) · Pathobiology · doi:10.1159/000123851 · Cited by 111
Prevalence of Early Onset Colorectal Cancer in 397 Patients With Classic Li–Fraumeni Syndrome
Wong, P., Verselis, S. J., Garber, J. E., Schneider, K. A., DiGianni, L. M., Stockwell, D. H., Li, F. P., & Syngal, S. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.10.014 · Cited by 111
Molecular pathology in basal cell cancer with p53 as a genetic marker
Pontén, F., Berg, C., Ahmadian, A., Ren, Z.-P., Nistér, M., Lundeberg, J., Uhlén, M., & Pontén, J. (1997) · Oncogene · doi:10.1038/sj.onc.1201435 · Cited by 110
Endometrial Glandular Dysplasia with Frequent p53 Gene Mutation: A Genetic Evidence Supporting Its Precancer Nature for Endometrial Serous Carcinoma
Jia, L., Liu, Y., Yi, X., Miron, A., Crum, C. P., Kong, B., & Zheng, W. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4837 · Cited by 110
Mechanisms for the involvement of DNA methylation in colon carcinogenesis.
Schmütte, C., Yang, A. S., Nguyen, T. T., Beart, R. W., & Jones, P. A. (1996) · PubMed · Cited by 103
p53 Codon 72 Polymorphism Predicts the Pathologic Response to Neoadjuvant Chemotherapy in Patients with Breast Cancer
Xu, Y., Yao, L., Ouyang, T., Li, J., Wang, T., Fan, Z., Lin, B., Lu, Y., & Xie, Y. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0507 · Cited by 102
The Combination of p53 Mutation and neu/erbB-2 Amplification Is Associated With Poor Survival in Node-Negative Breast Cancer
Bull, S. B., Özçelik, H., Pinnaduwage, D., Blackstein, M. E., Sutherland, D. A. J., Pritchard, K. I., Tzontcheva, A., Sidlofsky, S., Hanna, W. M., Qizilbash, A. H., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2004.09.128 · Cited by 99
A nucleotide substitution model with nearest-neighbour interactions
Lunter, G. A., & Hein, J. (2004) · Bioinformatics · doi:10.1093/bioinformatics/bth901 · Cited by 89
On the origin of G→T transversions in lung cancer
Pfeifer, G. P., & Hainaut, P. L. (2003) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/s0027-5107(03)00013-7 · Cited by 86
Self-citation
Inactivate the remaining p53 allele or the alternate p73? Preferential selection of the Arg72 polymorphism in cancers with recessive p53 mutants but not transdominant mutants
Tada, M. (2001) · Carcinogenesis · doi:10.1093/carcin/22.3.515 · Cited by 86
p53 germline polymorphisms are associated with an increased risk for breast cancer in German women.
Wang‐Gohrke, S., Rebbeck, T. R., Besenfelder, W., Kreienberg, R., & Runnebaum, I. B. (1998) · PubMed · Cited by 84
Restoration of transcriptional activity of p53 mutants in human tumour cells by intracellular expression of anti-p53 single chain Fv fragments
de Fromentel, C. C., Gruel, N., Venot, C., Debüssche, L., Conseiller, E., Dureuil, C., Teillaud, J., Tocqué, B., & Bracco, L. P. (1999) · Oncogene · doi:10.1038/sj.onc.1202338 · Cited by 83
TP53 mutation signature supports involvement of aristolochic acid in the aetiology of endemic nephropathy‐associated tumours
Nedelko, T., Arlt, V. M., Phillips, D. H., & Hollstein, M. C. (2008) · International Journal of Cancer · doi:10.1002/ijc.24006 · Cited by 82
Screening for TP53 rearrangements in families with the Li–Fraumeni syndrome reveals a complete deletion of the TP53 gene
Bougeard, G., Brugières, L., Chompret, A., Gesta, P., Charbonnier, F., Valent, A., Martin, C., Raux, G., Feunteun, J., Paillerets, B. B., et al. (2003) · Oncogene · doi:10.1038/sj.onc.1206155 · Cited by 82
Retention of the Arginine Allele in Codon 72 of the p53 Gene Correlates with Poor Apoptosis in Head and Neck Cancer
Schneider‐Stock, R., Mawrin, C., Motsch, C., Boltze, C., Peters, B., Hartig, R., Buhtz, P., Giers, A., Rohrbeck, A., Freigang, B., et al. (2004) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)63211-7 · Cited by 76
Evaluation of the Combined Effect of p53 Codon 72 Polymorphism and Hotspot Mutations in Response to Anticancer Drugs
Vikhanskaya, F., Siddique, M. M., Lee, M. K., Broggini, M., & Sabapathy, K. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1547 · Cited by 75
TP53 mutations in early-stage ovarian carcinoma, relation to long-term survival
Wang, Y., Helland, Å., Holm, R., Skomedal, H., Abeler, V. M., Danielsen, H. E., Tropé, C., Børresen-Dale, A.-L., & Kristensen, G. B. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601537 · Cited by 68
Intron variants of the p53 gene are associated with increased risk for ovarian cancer but not in carriers of BRCA1 or BRCA2 germline mutations
Wang‐Gohrke, S., Weikel, W., Risch, H. A., Vesprini, D., Abrahamson, J., Lerman, C., Godwin, A. K., Moslehi, R., Olipade, O., Brunet, J., et al. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690669 · Cited by 67
TP53 mutation, allelism and survival in non-small cell lung cancer
Nelson, H. H., Wilkojmen, M., Marsit, C. J., & Kelsey, K. T. (2005) · Carcinogenesis · doi:10.1093/carcin/bgi125 · Cited by 66
A functional screen for germ line p53 mutations based on transcriptional activation.
Frébourg, T., Barbier, N., Kassel, J., Ng, Y. S., Beer‐Romero, P., & Friend, S. H. (1992) · PubMed · Cited by 64
TP53 polymorphism, HPV infection, and risk of cervical cancer.
Klug, S. J., Wilmotte, R., Santos, C., Almonte, M., Herrero, R., Guerrero, I., Caceres, E., Guimarães, D. P., Lenoir, G., Hainaut, P. L., et al. (2001) · PubMed · Cited by 55
Self-citation
Effect of the codon 72 polymorphism (c.215G>C, p.Arg72Pro) in combination with somatic sequence variants in theTP53gene on survival in patients with advanced ovarian carcinoma
Wang, Y., Kringen, P., Kristensen, G. B., Holm, R., Baekelandt, M. M. O., Olivier, M., Skomedal, H., Hainaut, P. L., Trope, C. G., Abeler, V. M., et al. (2004) · Human Mutation · doi:10.1002/humu.20055 · Cited by 52
Self-citation
TP53 and P21 polymorphisms: Response to cisplatinum/paclitaxel-based chemotherapy in ovarian cancer
Santos, A. M., de Sousa, H. M. L., Portela, C. L., Pereira, D., Pinto, D., Catarino, R., Rodrigues, C., Araújo, A. P., Lopes, C., & Medeiros, R. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.11.176 · Cited by 51
MEF immortalization to investigate the ins and outs of mutagenesis
Brocke, J. V., Schmeiser, H. H., Reinbold, M., & Hollstein, M. C. (2006) · Carcinogenesis · doi:10.1093/carcin/bgl101 · Cited by 51
Common tumour p53 mutations in immortalized cells from Hupki mice heterozygous at codon 72
Reinbold, M., Luo, J.-L., Nedelko, T., Jerchow, B., Murphy, M. E., Whibley, C. E., Wei, Q., & Hollstein, M. C. (2007) · Oncogene · doi:10.1038/sj.onc.1210932 · Cited by 43
Two germ line polymorphisms of the tumour suppressor gene p53 may influence the biology of chronic lymphocytic leukaemia
Kochethu, G., Delgado, J., Pepper, C. J., Starczynski, J., Hooper, L., Krishnan, S., Fegan, C., & Pratt, G. (2006) · Leukemia Research · doi:10.1016/j.leukres.2005.12.014 · Cited by 34
Molecular precursor lesions in oesophageal cancer.
Montesano, R., & Hainaut, P. L. (1998) · PubMed · Cited by 34
Self-citation
HIPK2-induced p53Ser46 phosphorylation activates the KILLER/DR5-mediated caspase-8 extrinsic apoptotic pathway
Pistritto, G., Puca, R., Nardinocchi, L., Sacchi, A., & D’Orazi, G. (2007) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4402186 · Cited by 30
Clonal Analysis of Colorectal Tumors Using K-ras and p53 Gene Mutations as Markers
Dix, B. R., Robbins, P., Spagnolo, D. V., Padovan, G. L., House, A. K., & Iacopetta, B. J. (1995) · Diagnostic Molecular Pathology · doi:10.1097/00019606-199512000-00006 · Cited by 29
Tumor Susceptibility and Apoptosis Defect in a Mouse Strain Expressing a Human p53 Transgene
Dudgeon, C., Kek, C., Demidov, O. N., Saito, S., Fernandes, K., Diot, A., Bourdon, J., Lane, D. P., Appella, E., Fornace, A. J., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2063 · Cited by 25
p53 polymorphic variants at codon 72 and the outcome of therapy in randomized breast cancer patients
Wegman, P., Stål, O., Stenmark‐Askmalm, M., Nordenskjöld, B. A., Rutqvist, L., & Wingren, S. (2006) · Pharmacogenetics and Genomics · doi:10.1097/01.fpc.0000204997.84182.69 · Cited by 23
p53 Designer Genes for the Modern Mouse
Hergenhahn, M., Luo, J., & Hollstein, M. (2004) · Cell Cycle · doi:10.4161/cc.3.6.890 · Cited by 18
Arrayed Primer Extension Resequencing of Mutations in the TP53 Tumor Suppressor Gene: Comparison with Denaturing HPLC and Direct Sequencing
Calvez‐Kelm, F. L., Ahman, A., Tõnisson, N., Lambert, J., Temam, S., Brennan, P., Zaridze, D. G., Metspalu, A., & Hainaut, P. L. (2005) · Clinical Chemistry · doi:10.1373/clinchem.2005.048348 · Cited by 18
Self-citation
A double germline mutations in the APC and p53 genes.
Zajac, Tomka, M., Ilenčíková, D., Májek, P., Števurková, V., & Kirchhoff, T. (2000) · PubMed · Cited by 10
Single-Nucleotide Polymorphisms in the p53 PathwayPreprint
Harris, S. L., Gil, G. A., Hu, W., Robins, H. S., Bond, E. E., Hirshfield, K. M., Feng, Z., YU, X., Teresky, A. K., Bond, G. L., et al. (2005) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2005.70.024 · Cited by 9
Mouse models for generating P53 gene mutation spectra
Zielinski, B., Liu, Z., Hollstein, M. C., Hergenhahn, M., & Luo, J. (2002) · Toxicology Letters · doi:10.1016/s0378-4274(02)00160-1 · Cited by 5
Gene expression profiles and the TP53 mutation status are powerful prognostic markers of breast cancer
Langerød, A., Zhao, H., Borgan, Ø., Jm, N., Hernandez‐Boussard, T., Bukholm, I., Kåresen, R., Børresen‐Dale, A., & Jeffrey, S. S. (2005) · Breast Cancer Research · doi:10.1186/bcr1174 · Cited by 3

Research works printed but not linked: 1

Langerod A, Burdette L, Yeager M, Llaca V, Presswalla S, Gerhard DS et al. (2006a). Pattern of genetic variation in the tp53 locus indicates linkage disequilibrium extends across the flanking genes, ATP1B2 and WDR79. Hum Mutat (in press).

Sorted by citations

Blinded by the Light: The Growing Complexity of p53
Vousden, K. H., & Prives, C. (2009) · Cell · doi:10.1016/j.cell.2009.04.037 · Cited by 3,163
TP53 mutations in human cancers: origins, consequences, and clinical use.
Olivier, M., Hollstein, M., & Hainaut, P. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a001008 · Cited by 2,199
Self-citation
Breast Cancer—Epidemiology, Risk Factors, Classification, Prognostic Markers, and Current Treatment Strategies—An Updated Review
Łukasiewicz, S., Czeczelewski, M., Forma, A., Baj, J., Sitarz, R., & Stanisławek, A. (2021) · Cancers · doi:10.3390/cancers13174287 · Cited by 2,288
Mutant p53 in Cancer: New Functions and Therapeutic Opportunities
Muller, P. A. J., & Vousden, K. H. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.01.021 · Cited by 1,545
Mutant p53: one name, many proteinsPreprint
Freed-Pastor, W. A., & Prives, C. L. (2012) · Genes & Development · doi:10.1101/gad.190678.112 · Cited by 1,290

See all 884

Authors: Petitjean, A., Achatz, M. I. W., Borresen-Dale, A. L., Hainaut, P., & Olivier, M.
Affiliations: Centre international de recherche sur le cancer (FR)
Corresponding author: Hainaut, P
ORCID: Petitjean, A
Achatz, M I W
Hainaut, P
Olivier, M
Venue: Oncogene
Publisher: Springer Science and Business Media LLC
Published: 2007-04-02
Volume: 26
Issue: 15
Pages: 2157-2165
ISSN: 0950-9232 (ISSN-L)
1476-5594
DOI: 10.1038/sj.onc.1210302
OpenAlex: W2042484101
Cited by: 884
References: 117
Citations by year: 2026: 16 · 2025: 29 · 2024: 29 · 2023: 50 · 2022: 55 · 2021: 52 · 2020: 50 · 2019: 53 · 2018: 60 · 2017: 46 · 2016: 57 · 2015: 52 · 2014: 53 · 2013: 43 · 2012: 48
FWCI: 5.08
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
www.springer.com/tdm (vor)
Locations: Oncogene (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
Keywords: TP53 mutation, missense mutations, dominant-negative p53, gain-of-function, mutagenesis, tumor phenotype, cancer prognosis, Li-Fraumeni syndrome, loss of heterozygosity, breast cancer
MeSH terms: Genetic Markers, Humans, Mutation, Neoplasms, Polymorphism, Genetic, Prognosis, Biomarkers, Tumor, Tumor Suppressor Protein p53, Mutagenesis, Li-Fraumeni Syndrome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks